The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Safety Data From the Phase II JULIET Trial in DLBCL

Peter Borchmann, MD
Published Online:2:50 PM, Wed November 28, 2018


Peter Borchmann, MD, a professor in the department of internal medicine at the University Hospital of Cologne, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma (DLBCL).

With CAR T-cell therapies, cytokine relapse syndrome (CRS) and neurological events are of special interest in regard to safety. In this study, 58% of patients experienced CRS of some grade, but only 22% of patients experienced grade 3 or greater CRS.

Incidence of neurological events was also low; only 12% of patients reported grade 3 or greater. Cerebral edema was expected, but was not observed in this trial. Overall, Borchmann says tisagenlecleucel appeared safe in patients with DLBCL.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.